Genentech reported interim findings from a late-stage study showing that the combination of its drugs Avastin and Tarceva significantly prolonged survival in people with nonsmall-cell lung cancer without disease progression. The results prompted Genentech to halt the trial, indicating that the combination's "clinical benefit is likely quite significant," an analyst said.

Full Story:

Related Summaries